Drugs / Edecesertib
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04809623 | Sep 2021 → Oct 2022 | cutaneous lupus erythematosus | Gilead Sciences | Terminated | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05629208 | Apr 2023 → Dec 2025 | cutaneous lupus erythematosus | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT05165771 | Jul 2022 → Feb 2023 | rheumatoid arthritis | Gilead Sciences | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Edecesertib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05629208 ↗ |
| Known as | GS-5718 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05165771 ↗ |
| Modality | Small molecule | — CHEMBL5095097 ↗ |
| Route | Oral | “Tablets administered orally” NCT05165771 ↗ |